What is Brief History of Global Cord Blood Company?

Global Cord Blood Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

What is the history of Global Cord Blood Corporation?

Global Cord Blood Corporation is a key player in China's regenerative medicine sector, focusing on umbilical cord blood storage. A significant proposed acquisition in April 2022 highlighted its expansion goals, but also led to its current joint provisional liquidation.

Founded in 2003, the company began its commercial operations in Beijing, aiming to professionalize cord blood stem cell preservation. It has since become China's largest cord blood banking operator.

The company's history is marked by its growth into the largest operator in China, holding over 1 million stored units by March 2022. Its market dominance is shaped by China's regulatory environment, which generally permits only one cord blood bank per province. This strategic positioning, however, is currently impacted by its provisional liquidation status, leading to trading halts and delisting. Understanding this journey provides insight into the evolving cord blood banking industry in China and the company's future prospects. For a deeper dive into the external factors influencing the company, consider a Global Cord Blood PESTEL Analysis.

The journey of Global Cord Blood Company, initially established as China Cord Blood Corporation in 2003, began with a clear vision to provide essential cord blood banking services within China. This venture was a response to the growing recognition of regenerative medicine's potential and the need for secure stem cell storage solutions for expectant parents.

The Genesis of a Cord Blood Pioneer

Global Cord Blood Company's origins trace back to 2003, founded to meet the burgeoning demand for cord blood banking in China. The company's establishment was significantly bolstered by Golden Meditech, which secured a majority stake in the Beijing cord blood bank, marking a pivotal moment in the Revenue Streams & Business Model of Global Cord Blood.

• Founded in 2003 as China Cord Blood Corporation.
• Golden Meditech acquired a 51% stake in 2003.
• Mr. Yuen Kam, founder of Golden Meditech, became Chair of GCBC's board.
• Ms. Ting Zheng has been instrumental in operations and strategy since 2003.

The company's foundational business model focused on offering private cord blood storage to expectant parents, encompassing the collection, processing, and long-term preservation of stem cells. This model was intricately linked to China's regulatory framework, which mandated a 'one bank per province' licensing system. This unique structure required licensed entities to operate as both public (donation-based) and private (for-profit) banks, with revenue from private storage subscriptions supporting the public donation services.

The company's inception was driven by increasing global awareness of stem cell therapies and the specific healthcare needs prevalent in China during that period. Early financial backing was primarily sourced from initial capital investments and strategic alliances, with Golden Meditech's involvement being particularly crucial to its establishment and early growth.

Global Cord Blood SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The early growth of the company was marked by strategic expansion and a commitment to quality within China's developing cord blood banking sector. Following its initial commercialization, the company rapidly established itself as a key player. This period laid the groundwork for its future dominance in the industry.

Early Milestones and Quality Assurance

In 2005, the company's Beijing facility achieved ISO9001 certification, a significant early indicator of its dedication to high operational standards. This accreditation was crucial in building trust within the nascent cord blood banking market.

Geographical Expansion and Capacity Building

The company expanded its reach by acquiring the Guangdong Province Cord Blood Bank in 2007. Further enhancing its capabilities, capacity expansion at the Beijing Municipality Cord Blood Bank was completed in 2009.

Strategic Investments and International Standards

A substantial investment of US$65 million from KKR China Healthcare Investment Limited in 2012 provided significant capital for growth. By 2013, the Beijing facility earned AABB accreditation, demonstrating adherence to international quality benchmarks.

Subscriber Growth and Market Penetration

The company's subscriber base grew impressively, reaching over 500,000 by 2016 and exceeding 790,000 by 2019. Even during the challenging period of 2020-2022, it averaged over 75,000 new family bank subscribers annually.

Brand Evolution and Industry Positioning

In March 2018, the company rebranded from China Cord Blood Corporation to Global Cord Blood Corporation, signaling an ambition for international expansion. This strategic move aligned with industry consolidation trends and reinforced its leading position, operating with multiple licenses in a market typically allowing only one per province. This evolution reflects the Mission, Vision & Core Values of Global Cord Blood.

Global Cord Blood PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Global Cord Blood Company history is marked by significant achievements in establishing and expanding cord blood banking within China, alongside considerable recent challenges. Its origins trace back to 2003 when it became the first cord blood bank to commence commercial operations in China, laying foundational groundwork for the industry's development.

The company's innovations have centered on pioneering cord blood banking in a new market and achieving stringent quality accreditations. These efforts have positioned it as a leader in the cord blood industry's evolution.

Pioneering Commercial Operations

Established the first commercial cord blood bank in China, creating a new sector within the country's healthcare landscape.

Quality Accreditations

Achieved critical certifications like ISO9001 and AABB accreditation, setting high standards for operational quality and safety in cord blood storage.

Market Leadership Through Scale

Built the world's largest inventory of stored cord blood units, demonstrating significant operational capacity and market dominance.

Recent challenges for the Global Cord Blood Company have primarily stemmed from a proposed acquisition and subsequent shareholder disputes, leading to significant corporate governance issues. These events have impacted its public trading status and operational oversight.

Acquisition Dispute and Shareholder Opposition

A proposed $1 billion acquisition of Cellenkos Inc. faced strong shareholder opposition, citing concerns over purchase price, long-term value, and dilution, which significantly affected the company's stock performance.

Appointment of Joint Provisional Liquidators

The Grand Court of the Cayman Islands appointed Joint Provisional Liquidators in September 2022, suspending director powers and leading to the halting of trading on the NYSE.

Delisting and Legal Battles

The company's shares were delisted by the SEC in June 2023, and ongoing legal battles, including appeals related to subsidiary ownership in May 2025, highlight the complex aftermath of corporate governance disputes. Understanding the Target Market of Global Cord Blood provides context for its business model evolution.

Global Cord Blood Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The Global Cord Blood Company history is a narrative of pioneering growth in China's nascent cord blood banking sector, followed by significant corporate challenges. Established as China Cord Blood Corporation, it laid the groundwork for commercial cord blood banking in the nation.

Market Growth and Opportunity

The global cord blood banking services market was valued at US$32.2 billion in 2024 and is projected to reach US$47.9 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.8%. The China cord blood banking services market alone generated US$1,301.9 million in 2024 and is anticipated to reach US$2,483.6 million by 2030, exhibiting a robust CAGR of 11.8% from 2025 to 2030.

Regional Dominance and Drivers

Asia Pacific, including China, is expected to be the fastest-growing region in the cord blood banking sector. This growth is fueled by increasing public awareness, supportive healthcare policies, and high birth rates, creating a fertile ground for industry expansion.

Industry Advancements and Future Potential

The industry is experiencing continuous advancements in stem cell research, processing, and storage methods. There is a growing demand for stem cell therapies for conditions like cancer and genetic disorders, positioning major players to benefit significantly.

Navigating Challenges and Future Trajectory

Despite ongoing provisional liquidation, the core business of cord blood banking in China remains active. The future of Global Cord Blood Corporation hinges on resolving its provisional liquidation to capitalize on market growth and potentially re-engage with its strategic vision for the cell therapy market, as detailed in the Brief History of Global Cord Blood.

Global Cord Blood Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔